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Embryonic mouse upper-lip skin explants treated with
16.7 mM all-trans retinoic acid (tRA) give rise to a glandu-
lar metaplasia of hair vibrissa follicles; however, at this
concentration, tRA can activate not only the three retinoic
acid receptors (RARa, b, and g), but also the retinoid X
receptors (RXRa, b, and g) as a consequence of its
isomerization to 9-cis retinoic acid. We therefore studied
the respective roles of the RXR and RAR by treating
RARa–/–, b–/–, and g–/– skin explants with tRA and wild-
type explants with synthetic retinoids specific for RXR
or for each of the RAR. The null mutation of the RARa,
RARb, and RARg genes did not prevent tRA-induced hair
glandular metaplasia, but RARg inactivation dramatically
reduced its ratio. As demonstrated by treating explants
with a RAR- or a RXR-specific panagonist (CD367 and
For more than 40 y, it has been appreciated that vitamin Ais a critical regulator of growth and differentiation ofdeveloping adult mammalian and avian skin (reviewedby Means and Gudas, 1995). Vitamin A deficiency andhypervitaminosis A cause disruption of normal cellular
homeostatic mechanism, resulting in impairment of skin barrier func-
tion. More recent studies have shown that all-trans retinoic acid (tRA)
is the major biologic active form of vitamin A. Retinoids mediate
their effects through two families of nuclear receptors, each being
encoded by three genes: the retinoic acid receptors α, β, and γ (RARα,
β, and γ) and the retinoid X receptors α, β, and γ (RXRα, β, and γ),
(reviewed by Kastner et al, 1995; Mangelsdorf and Evans, 1995;
Chambon, 1996). Among the naturally occurring retinoids, tRA
activates RAR, whereas 9-cis-retinoic acid activates both RAR and
RXR. All-trans RA treatment has marked effects on embryonic skin
differentiation, leading to the exchange of one developmental pathway
for another: in the mouse, glomerular glands (GG) develop instead of
hair vibrissae in embryonic upper-lip skin (Hardy, 1968, 1983; Viallet
et al, 1991; Viallet and Dhouailly, 1994a). This homeotic-type effect
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Ro25–7386, respectively), RAR are primarily responsible
for this metaplasia. The use of two retinoids (Ro40–6055,
8 H 10–3 mM, or CD437, 7.7 H 10–2 mM) that are believed
to act, respectively, as a RARa- or a RARg-specific
agonist showed that both these receptors can initiate a
metaplasia. In contrast, BMS453, a RARb-specific agon-
ist, was unable to give rise to any metaplasia. Neverthe-
less, the highest degrees and ratios of metaplasia were
only obtained after treatment with the CD367 RAR
panagonist, or with either Ro40–6055 or CD437 at a
concentration sufficient to allow the activation of the
three RAR, suggesting that RARb activation is required
for a metaplasia of all vibrissæ. Key words: RAR null
mutants/RAR-specific agonists/RXR-specific agonists/skin
differentiation. J Invest Dermatol 111:206–212, 1998
is stage specific: it occurs only if exogenous tRA is added when hair
vibrissæ primordia are initiated (stages 1–3, as defined by Hardy, 1968)
in response to the dermal induction.
In the mouse, the skin develops two types of hair follicles: hair
pelage and, in the facial region, sensory hair follicles or vibrissæ, which
are mainly grouped around the mouth and the eyes. With the exception
of nasal and plantar sweat glands, the only glands present in mice skin
are tiny sebaceous glands (SG), each of which arises as a bud from one
side of the upper part of the pelage and vibrissa hair follicles. During
development, the formation of the first vibrissæ starts at 12 d post-
coitum, i.e., 2 d before the beginning of hair pelage formation. They
form in sequence along five rows on the upper-lip skin, so that several
developmental stages can be observed at the same time (Fig 1A). The
first step of hair vibrissa morphogenesis involves a placodal thickening
of the epidermis associated to a condensation of dermal cells (stage 1).
At stage 2, an epithelial column extends into the dermis. The dermal
papilla remains in association with the tip of the invaginating peg,
whose proximal end is first flat (stage 3a) and then concave (stages 3b,
c). Following this, the inner root sheath forms (stages 4, 5), and then
the hair shaft progressively develops and grows out of the skin (stages
6–8). The formation of the vibrissa-associated SG begins at stage 7.
Previous studies have shown that hair follicles form as a result of
reciprocal dermal–epidermal interactions (Dhouailly, 1977). It has been
proposed that the RAR may play a role in the establishment of the
dermal–epidermal interactions that lead to the formation of the hair
follicle. More precisely, the transcription of the RARα and γ genes
appears to be correlated with the manifestation of the inductive ability
of the embryonic dermal papilla, whereas the RARβ gene is not
transcribed at a detectable level during mouse skin morphogenesis
(Viallet and Dhouailly, 1994b). Targeted disruption through homolog-
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Figure 1. Distribution pattern of mouse WT upper-lip hair vibrissæ.
(A) Isolated epidermis from a 13.5 d embryo, showing five rows of vibrissa
anlagen from placodal (PA) to hair peg (PG) stages. Osmium tetroxyde fixation.
Scale bar, 200 µm. (B) Tangential and partial section of a control 13.5 d explant
after 48 h in vitro followed by 10 d onto nude mice kidney: differentiation of
three rows of hair vibrissa follicles (VF), intermingled with numerous hair
pelage follicles (HP). Hematoxylin/Biebrich scarlet staining. Scale bar, 100 µm.
D/V, dorso/ventral; O/N, ocular/nasal.
ous recombination of the RARα (Lufkin et al, 1993) or the RARγ
(Lohnes et al, 1993), however, as well as that of both these receptors
(Lohnes et al, 1994), does not appear to lead to an impairment of
cutaneous appendages morphogenesis. As expected, RARβ knockout
also has no effect on skin development (Ghyselinck et al, 1997).
The treatment of these three RAR null mutants with tRA, by
comparison with wild-type (WT) embryos, and the use of synthetic
retinoids that selectively activate all RAR or RXR, or only one
member of the RAR family, now give new opportunities to analyze
the role of the RAR in tRA induced glandular metaplasia. In this
study, we first checked whether the RARα, β, or γ knockout does
not alter the response to the tRA treatment. RAR null mutants, and
especially double knockout mutants, have a very reduced viability, and
thus are very difficult to obtain in large numbers. Furthermore, tRA
may possibly transactivate the RXR through isomerization (Heyman
et al, 1992; Levin et al, 1992; Allegretto et al, 1993). We therefore used
synthetic retinoids specific either for the RAR or for the RXR to
discern the respective involvement of these receptors in tRA induced
glandular metaplasia. A complementary study, using RAR agonists
with different specificities, gave us a further insight about the respective
ability of the RARα, β, and γ to induce a glandular metaplasia of hair
vibrissa follicles.
MATERIALS AND METHODS
Obtention of embryos WT embryos were obtained by mating Swiss OF1
mice overnight. Females were examined for a vaginal plug the following
morning. The day of the vaginal plug was designated as 0.5. The generation
of RARα, β, or γ single null mutants has been described (Lufkin et al, 1993;
Lohnes et al, 1993; Ghyselinck et al, 1997). Embryos were obtained by mating
RARα, β, or γ appropriate heterozygotes. Genotypes were determined by
genomic Southern blotting using DNA isolated from embryonic tissues. Probe,
digest, and other conditions for Southern blotting have been detailed elsewhere
(Lufkin et al, 1993; Lohnes et al, 1993; Ghyselinck et al, 1997).
In vitro culture and graft of skin explants The embryonic upper-lip skin
was dissected at 13.5 d of gestation. Explants were cultured in vitro by placing
them onto a grid in a Falcon dish containing Dubelcco’s modified Eagle’s
medium, 20% fetal calf serum, and the retinoid of interest or its solvent alone.
Culture dishes were incubated for 2 d at 37°C in a 5% CO2 atmosphere.
Explants were then grafted onto nude mice kidney and allowed to develop for
10 d. After fixation in 4% formaldehyde for 12 h, the explants were dehydrated
and embedded in paraffin. Transversal or sagittal sections (7 µm) were stained
with Hematoxylin/Biebrich scarlet and allowed for histologic analysis.
Retinoids assays tRA, Ro25–7386 (RXR panagonist or pan-RXR) and
Ro40–6055 (5 AM580, RARα-specific agonist) were a gift from Dr. M.
Klaus (Hoffman-la Roche, Basel, Switzerland); CD367 (RAR panagonist or
pan-RAR) and CD437 (RARγ-specific agonist) were provided by
Dr. M. Demarchez (CIRD-Galderma, Sophia Antipolis, France); BMS453
(RARβ-specific agonist) and BMS649 (another pan-RXR) were obtained from
BMS Pharmaceutical Research Institute (Buffalo, NY). tRA was dissolved in
absolute ethanol from which fresh dilution was made before use. Synthetic
retinoids were dissolved in dimethylsulfoxide. In each experiment, controls
were run using the same concentration of solvent (either ethanol or dimethylsul-
foxide) as used in the experiment plates. Retinoids were used in the tissue
culture medium at the following concentrations: tRA, 16.5 µM; CD367
(pan-RAR), 10–3, 1, or 10 µM; Ro25–7386 (pan-RXR), 10–3, 1, or 10 µM;
Ro40–6055, 10–3, 8 3 10–3 (concentration recommended for RARα specifi-
city), 10–2, 10–1, or 1 µM; BMS453, 10–3, 10–2, 10–1 (concentration recom-
mended for RARβ specificity), or 1 µM; CD437, 10–3, 10–2, 7.7 3 10–2
(concentration recommended for RARγ specificity), 10–1, or 1 µM; BMS649
(pan-RXR), 10–1 µM. All procedures involving manipulation of retinoids were
performed in dim light.
RESULTS
RARa, b, or g null mutation does not impair the proper
development of mouse upper-lip skin At 13.5 d of gestation, the
morphology of the RARα–/–, β–/–, and γ–/– explants was similar to
that of the WT explants: their vibrissæ were also distributed in five
rows, the posterior and ventral vibrissæ, respectively, developing earlier
than the anterior and dorsal ones, as shown for a WT explant (Fig 1A,
B). After 2 d in vitro followed by 10 d on the nude mice kidney, the
appearance of the RARα–/–, β–/–, and γ–/– explants was similar to
that of the WT. In particular, the morphology of the hair and vibrissa
follicles was identical to that of the WT standards (Fig 2A, C, E, G),
with the usual small SG connected to the upper part of the follicles
(not shown).
RARg knockout dramatically decreases the ratio of tRA-
induced glandular metaplasia We then checked the ability of skin
explants derived from 13.5 d RARα–/–, β–/–, or γ–/– null mutant
embryos to respond to the tRA treatment. Unexpectedly, all three
kinds of explants were still able to give rise to a glandular metaplasia
of vibrissæ (Fig 2D, F, H), the morphology of the glands being similar
to those obtained with the WT explants (Fig 2B). Some vibrissæ
totally disappeared and were replaced by a GG displaying a small
glomerule and a duct opening directly onto the surface of the epidermis
(Fig 2B, D, F). Secretory elements were present in the lumen of some
glomerules, suggesting that the corresponding glands were active
(Fig 2D). In a few cases, the glomerule did not form, and the gland
was restricted to a duct that probably represents an incomplete type of
metaplasia (not shown). Furthermore, some glands appeared to grow
out from the outer root sheath of the hair vibrissa follicles (Fig 2H).
These vibrissa-associated glands (AGG) nevertheless displayed a glomer-
ule and a duct similar to those of the GG. The localization of the duct
connection was not conserved among the different follicles: some ducts
grew out from the basis of the follicle whereas others grew from the
upper third.
Whereas tRA induced a glandular metaplasia in all WT,
RARα–/–, and β–/– explants, only three of five treated γ–/– explants
actually responded (Table I). Furthermore, RARα–/– and β–/– explants
presented an identical (50%) ratio of vibrissa glandular metaplasia
(calculated as the mean percentage of vibrissæ transformed into glands)
(Fig 3): this ratio is not very different from that of the WT explants
(58%). In contrast, only 20% of the vibrissæ of the responsive RARγ–/–
explants gave rise to a glandular metaplasia. It should be noted that
the total mean number of appendages (involving vibrissæ and glands)
per explant after tRA treatment was of the same order for all four
genotypes. The occurrences of the three types of metaplasia obtained
with the four genotypes are summarized in Table I. The ratio of AGG
was comparable for the three kinds of mutants, and not significantly
different from the one obtained with the WT explants; however, the
degree of metaplasia (i.e., the ratio of GG versus AGG) varies between
1 (RARγ–/–), 1.8 (WT), 2.7 (RARα–/–), and 3 (RARβ–/–). The
RARγ–/– explants thus displayed the lowest ratio as well as the lowest
degree of glandular metaplasia.
Panagonist specific for RAR, but not for RXR, can transform
almost all vibrissæ into glands RAR null mutants, and especially
double knockout mutants, have a very reduced viability, thus impairing
their use in a large series of grafting experiments. Furthermore, tRA
may possibly transactivate the RXR through its isomerization (Heyman
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Figure 2. tRA induces a hair vibrissa metaplasia in mouse upper-lip
skin explants from WT embryos as well as from RARa–/–, b–/–, or g–/–
null mutants. Upper-lip skin explants from 13.5 d embryos were cultured
in vitro for 2 d in the absence (–RA) or the presence (1RA) of 16.5 µM tRA.
They were then grafted onto nude mice kidney for 10 d. Untreated WT (A)
as well as RARα–/– (C), RARβ–/– (E), and RARγ–/– (G) explants developed
normal vibrissa and pelage hair follicles. After tRA treatment, similar glandular
structures were observed in WT (B), RARα–/– (D), RARβ–/– (F), and
RARγ–/– (H) explants. (A–F) Longitudinal sections. (G, H) Transversal sections.
AGG, Glomerular gland associated with a vibrissa; DC, duct; DP, dermal
papilla; E, epidermis; GG, glomerular gland; HP, hair pelage follicle; HS, hair
shaft; IRS, inner root sheath; L, lumen; ORS, outer root sheath; SG, sebaceous
gland; VF, hair vibrissa follicle. (A–H) Hematoxylin/Biebrich scarlet staining.
Scale bar, 100 µm.
et al, 1992; Levin et al, 1992; Allegretto et al, 1993). We therefore used
synthetic retinoids specific either for the RAR (the pan-RAR CD367)
or for the RXR (the pan-RXR Ro25–7386) to discern the respective
involvement of these two families of receptors in tRA induced glandular
metaplasia. All explants treated with one of these two molecules gave
rise to a glandular metaplasia of vibrissæ (Table II). Futhermore, at
10–3 µM, the pan-RAR resulted in a metaplasia of about 90% of the
vibrissæ (Fig 4A). Increasing the dose of the pan-RAR led to a
complete disappearance of typical vibrissa follicles. In contrast, after a
treatment with 10–3 µM pan-RXR, only 20% of the vibrissæ of each
explant gave rise to a glandular metaplasia (Fig 4B). Even at a 10,000
times higher concentration (10 µM), the Ro25–7386 pan-RXR failed
to transform all the vibrissæ into glands. Accordingly, another pan-
RXR (BMS649, 10–1 µM) also gave a similar ratio of metaplasia (data
not shown).
When compared with tRA treatment, the degree of metaplasia was
significantly higher after 10–3 µM pan-RAR treatment: about 45% of
hair vibrissa follicles were changed into GG, and the AGG and duct
types were never observed (Table II). Furthermore, the morphology
of the GG was slightly different: glomerules were larger, with a wider
lumen, and there were branched ducts like in salivary glands (Fig 5B).
Moreover, a further 45% of vibrissæ gave rise to a supplementary type
of vibrissa metaplasia, characterized by a hyperdevelopment of the
SG (Fig 5A, C). The most frequent transformation (about 30%)
corresponded to a hyperdeveloped SG associated with a GG (GSG in
Table II). A few hyperdeveloped SG were also found associated with
an AGG, and some SG developed without any GG adjunction (not
shown), thus resembling the SG present in the human ear and nose
skin. Finally, the remaining 10% vibrissa follicles were all associated
with abnormally developed SG. Although secretion granules were
present in the lumen of all the glomerules (not shown), only a few
ducts actually opened into the epidermis, most of them presenting a
dead end. Increasing the concentration of the pan-RAR resulted in a
nearly equal proportion of GG and GSG and a dramatic decrease of
the SG ratio.
Agonists specific either for RARa or for RARg, but not for
RARb, can initiate a glandular metaplasia of WT explants To
establish if the activation of a single RAR is sufficient to induce a
glandular metaplasia, WT explants were treated with three synthetic
retinoids (Ro40–6055, BMS453, and CD437) displaying different
transactivation abilities for the three RAR. At 8 3 10–3 µM, Ro40–
6055 is believed to act as a RARα-specific agonist (Apfel et al, 1992,
1995). Nevertheless, it transformed about 28% of the vibrissæ into GG
(Fig 4C, Table II). Similarly, at 7.7 3 10–2 µM, a concentration at
which it has been shown to specifically transactivate RARγ (Martin
et al, 1992), CD437 gave rise to the same ratio of GG metaplasia
(Fig 4D, Table II). Strikingly, the treatment with both these molecules
did not increase the ratio of vibrissa metaplasia (Table II); however,
all the four explants responded when treated with both these molecules,
whereas only five of six or four of five of the explants, respectively,
treated with Ro40–6055 or CD437 gave rise to glandular metaplasia.
On the other side, at 10–1 or 1 µM, BMS453 acts as a RARβ-specific
agonist as well as a RARα and RARγ antagonist (Chen et al, 1995).
As shown in Table II, none of the 13 explants treated with 10–1 µM
BMS453, nor the two explants treated at the dose of 1 µM, exhibited
any vibrissa metaplasia.
On a second occasion, we checked the effects of increasing the dose
of Ro40–6055 or CD437. In both cases, increasing the dose enhanced
the ratio of vibrissa metaplasia (Fig 4C, D, Table II), but should also
lead to the lack of RAR specificity (Martin et al, 1992). Higher doses
of Ro40–6055 gave rise to a hypertrophy of SG, so that, at 1 µM, the
distribution of the GG, hyperdeveloped sebaceous glands associated
with an AGG, and GSG was nearly identical to that previously obtained
when using the CD367 pan-RAR at the same concentration. In
contrast, explants treated with CD437 only displayed GG and AGG.
DISCUSSION
None of the RARα–/–, β–/–, and γ–/– null mutants presented any
apparent defect in appendage morphogenesis. Consequently, none of
the three RAR appeared to be absolutely required for a proper hair
vibrissa follicle differentiation, at least in the surviving embryos. More
precisely, it suggests that the two RAR detected in skin, i.e., the
RARα and γ (Elder et al, 1991; Fisher et al, 1994; Viallet and Dhouailly,
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Table I. RARg knockout dramatically reduces the ratio of retinoic acid-induced glandular metaplasiaa
% metaplasiae
Genotype Explantsb Appendagesc % Vibrissæd AGG D GG
Wild-type 5 [5] 141 [28.2] 41.8 (64.2) 17.7 (63.2) 8.5 (62.3) 31.9 (63.9)
RARα–/– 4 [4] 92 [23.0] 50.0 (65.2) 13.0 (63.5) 2.2 (61.5) 34.8 (65.0)
RARβ–/– 4 [4] 98 [24.5] 50.0 (65.1) 10.2 (63.1) 9.2 (62.9) 30.6 (64.7)
RARγ–/– 5 [3] 139 [27.8] 79.9 (63.4) 9.4 (62.5) 1.4 (61.0) 9.4 (62.5)
aFor each embryo, one explant was treated with 16.5 µM all-trans retinoic acid, while the contralateral explant was treated with ethanol alone. No glandular metaplasia was observed
in these controls.
bNumber of treated explants. The number of explants having given rise to glandular metaplasia is indicated into brackets.
cTotal number of appendages onto the treated explants. The mean number of appendages per treated explant are given in brackets.
dPer cent normal vibrissæ 6SD.
ePer cent transformed appendages 6SD. AGG, glomerular gland associated with a vibrissa; D, duct not connected to a glomerule; GG, glomerular gland.
Figure 3. RARg knockout dramatically decreases the response to tRA
treatment. Bars represent the percentage of vibrissæ that were transformed
into glands in explants of 13.5 d WT, RARα–/–, RARβ–/–, or RARγ–/–
embryos treated for 2 d with 16.5 µM tRA and processed as in Fig 2. Error
bars, mean 6 SD.
1994b), can substitute for each other. This is in agreement with
the presence of phenotypically normal hairs and whiskers in adult
RARα–/–, β–/–, and γ–/– mice. This is further evidence of the functional
redundancy previously observed between RARα and γ (Lufkin et al,
1993; Lohnes et al, 1993; Ghyselinck et al, 1997); however, as previously
shown using RARα–/– or RARγ–/– knockout F9 cells, such a
redundancy, which can be artificially generated by gene knockout,
does not necessarily imply that these two receptors usually control the
transcription of the same set of genes (Taneja et al, 1996).
RAR are the primary effectors of the upper-lip skin glandular
metaplasia It is known that tRA can isomerize into 9-cis retinoic
acid that binds RAR as well as RXR (Heyman et al, 1992; Levin et al,
1992; Allegretto et al, 1993); however, CD367, a pan-RAR with no
effect onto RXR (Xiao et al, 1995), was able not only to induce the
hair vibrissa metaplasia in all treated explants, but also to transform
100% of the vibrissæ into glands and to produce a SG hyperplasia,
strongly suggesting that the RAR are the primary effectors of vibrissa
metaplasia. That tRA treatment never gives rise to a SG hypertrophy
may possibly arise from its rapid metabolism in vivo. Similarly, Feng
et al (1997) established that tRA and the RAR-selective ligand
CD367, but not the RXR-selective ligand SR11237, can induce the
transcription of the CRABPII, CRBPI, and CRBPII in mouse
epidermis in vivo. Under these conditions, why should the treatment
with a pan-RXR (either Ro25–7386 or BMS649) also transform a
few follicles of all treated explants into glands? It has been progressively
established that RXR/RAR heterodimers are the functional units that
preferentially transduce the retinoid signal to activate the expression
of target genes (Chambon, 1996, and references therein), especially
in vivo in the mouse (Kastner et al, 1997) and in cultures of human
keratinocytes (Xiao et al, 1995). The concomitant administration of
suboptimal concentrations of RAR- and RXR-specific ligands to
cultured embryonal carcinoma P19 and F9 cells was shown to result
in the synergistic activation of the expression of a number of endogenous
retinoic acid-responsive genes (Roy et al, 1995; Taneja et al, 1996). It
is thus conceivable that the pan-RXR treatment of the upper-lip skin
may allow such a synergistic activation of RXR/RAR heterodimers
together with the endogenous retinoids. Alternatively, the RXR were
shown to function as promiscuous heterodimeric partners for several
nuclear receptors, including the peroxysome proliferators-activated
receptors, the liver X receptors, and the orphan receptor NGFI-B.
Taking into account that the RXR are ligand responsive when
heterodimerized with one of these receptors (Perlman and Janson,
1995; DiRenzo et al, 1997; Willy and Mangelsdorf, 1997), it is possible
that the pan-RXR treatment could interfere with another receptor
pathway. For example, Kang et al (1997) demonstrated that the 9-cis
retinoic acid treatment of human skin can enhance the stimulation of
the transcription of the 24-hydroxylase gene by the 1,25-dihydroxyvita-
min D3-liganded vitamin D receptor/RXR heterodimer. A further
study of genes whose expression is perturbated in hair glandular
metaplasia is thus obviously required to understand the molecular bases
of this phenomenon; however, one major limitation in interpreting
experiments with synthetic retinoids is that little is known about the
variability in their uptake and/or their intracellular concentration in
the different mouse embryonic or adult organs. Furthermore, activation
of RAR by synthetic retinoids is not necessary functionally equivalent
to activation by tRA.
RARg, whose knockout significantly reduces the response to
the tRA treatment, seems able to induce a glandular metaplasia
without the need of RARa and b activation The treatment of
RARα–/– explants with tRA indicated that RARγ is able to initiate a
glandular metaplasia of vibrissæ, considering that no RARβ transcript
can be detected in mouse upper-lip skin (Viallet and Dhouailly, 1994b).
Only three RARγ–/– explants responded to the treatment, however,
and moreover at a ratio and a degree (ratio of GG versus AGG) of
vibrissa metaplasia significantly lower than the explants of the three
other genotypes. This is in agreement with the fact that RARγ is
believed to be much more abundant than RARα in mouse embryonic
skin, as suggested by their respective transcript levels in WT mouse
embryo (Viallet and Dhouailly, 1994b) and the dosage of the RAR in
human (88% RARγ versus 12% RARα, Fisher et al, 1994). The lower
response of the RARγ–/– upper-lip skin may also arise from the fact
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Table II. RARa and g are the primary effectors of retinoid-induced glandular metaplasia of vibrissæ
% Metaplasiad
Retinoids (µM) Explantsa Appendagesb % Vibrissæc AGG D GG AGS GSG SG
CD367 10–3 5 [5] 119 [23.8] 10.1 (62.8) – – 43.7 (64.5) 4.2 (61.8) 29.4 (64.2) 12.6 (63.0)
1 4 [4] 72 [18.0] – – – 36.1 (65.7) 4.2 (62.4) 58.3 (65.8) 1.4 (61.4)e
10 4 [4] 64 [16.0] – – – 42.2 (66.2) 7.8 (63.4) 48.4 (66.2) 1.6 (61.6)e
Ro25-7386 10–3 3 [3] 85 [28.3] 80.0 (64.3) 8.2 (63.0) – 10.6 (63.3) – – 1.2 (61.2)e
1 3 [3] 85 [28.3] 36.5 (65.2) 21.2 (64.4) – 29.4 (64.9) 1.2 (61.2)e 11.8 (63.5) –
10 4 [4] 91 [22.8] 68.1 (64.9) 18.7 (64.1) – 12.1 (63.4) – 1.1 (61.1)e –
Ro40-6055 10–3 3 [0] 48 [16.0] 100 – – – – – –
8 3 10–3 6 [5] 115 [19.2] 72.2 (64.2) 8.7 (62.6) 1.7 (61.2) 17.4 (63.5) – – –
10–2 7 [7] 142 [20.3] 69.7 (63.9) 19.7 (63.3) – 10.6 (62.6) – – –
10–1 7 [7] 118 [16.9] 20.3 (63.7) 58.5 (64.5) – 13.6 (63.2) 1.7 (61.2) 5.1 (62.0) 0.8 (60.8)e
1 5 [5] 102 [20.4] 1.0 (61.0) 10.8 (63.1) – 30.4 (64.6) 2.9 (61.7) 54.9 (64.9) –
BMS453 10-3 4 [0] 93 [23.3] 100 – – – – – –
10–2 3 [0] 69 [23.0] 100 – – – – – –
10–1 13 [0] 271 [20.8] 100 – – – – – –
1 2 [0] 41 [20.5] 100 – – – – – –
CD437 10–3 6 [0] 140 [23.3] 100 – – – – – –
10–2 6 [0] 119 [19.8] 100 – – – – – –
7.7 3 10–2 5 [4] 110 [22.0] 71.8 (64.3) 11.8 (63.1) 1.8 (61.3) 14.5 (63.4) – – –
10–1 5 [5] 127 [25.4] 89.8 (62.7) 7.1 (62.3) – 3.1 (61.5) – – –
1 5 [5] 127 [25.4] 25.2 (63.9) 70.1 (64.1) – 4.7 (61.9) – – –
Ro40-6055 1 CD437f 4 [4] 85 [21.3] 76.5 (64.6) 9.4 (63.2) – 14.1 (63.8) – – –
aNumber of treated explants. The number of explants having given rise to glandular metaplasia is indicated into brackets.
bTotal number of appendages onto the treated explants. The mean number of appendages per treated explant are given into brackets. For each embtyo, one explant was treated with
the indicated retinoid, while the contralateral explant was treated with DMSO alone. No glandular metaplasia was observed in these controls.
cPer cent normal vibrissæ 6SD.
dPer cent transformed appendages 6SD. AGG, glomerular gland associated with a vibrissa; D, duct not connected to a glomerule; GG, glomerular gland; SG, hupertrophied sebaceous
gland; GSG, glomerular gland associated with a SG; AGS, AGG associated with a SG.
eOne unique appendage displayed this type of metaplasia.
fExplants were simultaneously treated with 8 3 10–3 µM Ro40-6055 and 7.7 3 10–2 µM CD437.
Figure 4. The activation of more than one RAR is required to reach
the highest ratios of vibrissa metaplasia. WT explants were treated with
(A) the CD367 RAR pan-agonist; (B) the Ro25–7386 RXR pan-agonist; (C)
Ro40–6055, believed to be RARα-specific at 8 3 10–3 µM; (D) CD437,
believed to be RARγ-specific at 7.7 3 10–2 µM. Bars represent the percentages
of vibrissæ transformed into glands in WT 13.5 d upper-lip skin explants treated
for 2 d with the indicated retinoid and processed as in Fig 2. Concentrations
are given in µM. Error bars, mean 6 SD.
that, although RARα and γ transcripts are both present in the dermis
and epidermis of 13.5 d WT embryos, RARα transcripts are no longer
detectable in these tissues 2 d later (Viallet and Dhouailly, 1994b),
suggesting that RARα is not present in embryonic skin at this stage
of development. Thus, at this moment, the RARγ knockout may lead
to the lack of RAR in embryonic skin, except a low level of tRA-
induced RARβ. Furthermore, taking into account that the follicles of
one given explant are not at the same stage of development and can
only respond during a narrow temporal window (stages 1–3), one can
imagine that the RARγ knockout may either reduce this window or
impair the response of the more advanced vibrissæ.
At 7.7 3 10–2 µM, the CD437 retinoid is believed to be specific
for RARγ (Martin et al, 1992); however, it truely induced a glandular
metaplasia at this dose, thus suggesting that the activation of the two
other RAR, especially RARα, also present in skin, is not an absolute
requirement. Nevertheless, we cannot rule out that some activation of
RARα may also have occurred through the endogenous retinoids. In
any case, even at 1 µM, the CD437 RAR selective-retinoid transformed
no more than 75% of vibrissæ into glands, and the ratio of GG versus
AGG was below 1. Furthermore, no vibrissa displayed SG hypertrophy
after this treatment. These results, which are different from those
obtained using the CD367 pan-RAR, suggest that the highest ratios
and degrees of metaplasia, as well as the SG hypertrophies, require the
activation of at least two RAR.
The RARa is able to initiate a glandular metaplasia of vibrissæ,
at least when the RARg is absent or not activated Taking into
account the lack of RARβ in mouse upper-lip skin, the tRA treatment
of RARγ–/– explants unambiguously demonstrated that RARα is able
to initiate a glandular metaplasia of vibrissæ, at least in the absence of
RARγ. This result is confirmed by the observation that the treatment
of WT explants with 8 3 10–3 µM Ro40–6055 (a concentration at
which this retinoid is believed to be specific for the RARα, Apfel
et al, 1992, 1995) also induced this metaplasia. Increasing the dose of
Ro40–6055 from 8 3 10–3 to 10–1 µM concurrently increased the
ratio of vibrissa metaplasia from about 30% to 80%, but the ratio of
GG did not grow accordingly, so that the ratio of GG versus AGG
decreased from 2 to 0.2. Interestingly, 10–1 µM Ro40–6055 also
induced a SG hypertrophy. At the highest used dose (1 µM), the ratios
of both the GG and the GSG were nearly identical with those obtained
when treating the WT explants with the same concentration of the
CD367 pan-RAR. We must obviously keep in prudence with the
interpretation of receptor-selective ligand effects, considering that the
variability in the uptake and/or the intracellular metabolism of the
different retinoids in mouse embryonic or adult skin is unknown. As
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Figure 5. Treatment with a RAR pan-
agonist induces not only a hair vibrissa
metaplasia, but also a sebaceous gland
hypertrophy. Explants of 13.5 d upper-lip
skin were treated for 2 d with the CD367
RAR pan-agonist (10–3 µM) and processed
as in Fig 2. (A) Overview showing several
glomerular glands associated with GSG and
a complete disappearance of hair vibrissa
follicles. Only some hair pelage follicles
(HP) are formed (compare with the control,
Fig 1B). (B) Detail of a glomerular gland
with a branched duct (BDC) and secretories
elements (SE). (C) Detail of a GSG. G,
Glomerule; L, lumen. (A–C) Hematoxylin/
Biebrich scarlet staining. Scale bar, 100 µm.
the Kds of Ro40–6055 for RARα, β, and γ are, respectively, 8, 131,
and 450 nM (Apfel et al, 1992, 1995), however, it is probable that at
least a part of the effects obtained at the highest concentrations of
Ro40–6055 arose through the activation of one of the two other
RAR, or both. In other words, Ro40–6055 should progressively
behave as a pan-RAR in proportion as the dose is increased.
RARb-specific agonist cannot initiate a glandular metaplasia,
but the RARb may act synergistically with the two other RAR
to increase the degree of metaplasia None of the explants treated
with the BMS453 RARβ-specific agonist gave rise to a glandular
metaplasia. This result is in agreement with the lack of RARβ
transcripts in embryonic mouse upper-lip skin (Viallet et al, 1991;
Viallet and Dhouailly, 1994b). This suggests that the RARβ is not
required for the induction of glandular metaplasia, as already shown
when tRA-treated heterotopic recombinants of upper-lip epidermis
and dorsal dermis resulted in glands formation without induction of
RARβ transcription (Viallet and Dhouailly, 1994b); however, it should
be reminded that tRA induces the transcription of the RARβ gene in
upper-lip skin (Viallet et al, 1991). The fact that the highest degrees
and ratios of metaplasia as well as a SG hyperdevelopment were
obtained by treatment either with CD367 or with Ro40–6055 (only
at the highest doses for the latter), but not with a combination of Ro40–
6055 and CD437 at the concentration where these two molecules are
believed to be, respectively, specific for RARα and RARγ, strongly
suggests that RARβ activation may also be required. Unfortunately, it
was not possible to test directly with the WT explants whether RARβ
should act synergistically with either RARα or RARγ, or both these
receptors, because the BMS453 RARβ-specific agonist also displays a
RARα- and RARγ-antagonistic activity (Chen et al, 1995). This
question remains to be addressed by using other retinoids, or, more
rigorously, by treating explants from the different null mutants with a
pan-RAR. It also remains to identify the genes whose expression is
perturbated following retinoid exposure of mouse upper-lip skin.
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